Volume 20, Number 6—June 2014
Research
Characteristics of Patients with Mild to Moderate Primary Pulmonary Coccidioidomycosis
Table 2
Study end point | Antifungal treatment |
p value | |||
---|---|---|---|---|---|
Yes, n = 20 | No, n = 16 | ||||
Time to 50% reduction in symptom score, wk | 0.84† | ||||
Median | 9.9 | 9.1 | |||
Q1, Q3 | 7.0, 13.4 | 7.4, 17.1 | |||
Range |
4.0–24.0 |
3.7–24.4 |
|||
Time to complete symptom resolution, wk | 0.65‡ | ||||
Median | 18.7 | 17.8 | |||
Q1, Q3 | 13.6, 25.0 | 12.1, 24.0 | |||
Range |
8.9–29.6 |
8.7–27.1 |
|||
Time to 50% reduction in fatigue, wk§ | 0.59‡ | ||||
Median | 12.9 | 9.8 | |||
Q1, Q3 | 8.0, 16.0 | 8.4, 15.9 | |||
Range |
5.0–29.6 |
4.4–25.6 |
|||
Time to full attendance at work, wk | 0.02† | ||||
Median | 8.4 | 5.7 | |||
Q1, Q3 | 6.7, 14.8 | 5.1, 6.0 | |||
Range |
9.0–29.6 |
2.4–7.6 |
|||
Time to full attendance at school, wk | |||||
Median | 13.7 | ||||
Q1, Q3 |
13.7, 13.7 |
||||
Time to 50% improvement in PCS, wk | 0.08‡ | ||||
Median | 20.4 | 13.8 | |||
Q1, Q3 |
14.7, 26.0 |
10.4, 18.0 |
|||
Time to 50% improvement in MCS, wk | 0.21‡ | ||||
Median | 12.0 | 8.1 | |||
Q1, Q3 | 9.3, 14.7 | 6.6, 9.7 |
*Q1, first quartile; Q3, third quartile; PCS, physical activity score as measured on the SF-36 General Health Survey; MCS, mental activity score as measured on the SF-36 General Health Survey.
†By the Wilcoxon rank–sum test.
‡By the equal variance t test.
§As reported on the Fatigue Severity Scale.
Page created: May 16, 2014
Page updated: May 16, 2014
Page reviewed: May 16, 2014
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.